Prevention Research Center to study benefits of home-based exercise in heart failure

October 31, 2001

The Yale-Griffin Prevention Research Center, part of the Yale School of Medicine, has been awarded a two-year, nearly $200,000 grant from the Centers for Disease Control & Prevention to investigate the benefits of a home-based exercise program for patients with Congestive Heart Failure (CHF).

The study will determine the effectiveness of a tailored, home-based exercise regimen on quality of life and functional capacity, and will measure such outcomes as hospitalization rates, emergency department visits and quality of life.

"This study is very exciting," said principal investigator David L. Katz, M.D., associate clinical professor in the Department of Epidemiology and Public Health at Yale School of Medicine "because it explores a way to improve health and function in heart failure patients without relying solely on medication. We also hope to show that this approach is financially practical, meaning that heart failure care costs less with this program than without it."

The current study builds on the success of a Chronic Disease Management Program for Heart Failure, developed by Griffin Hospital, and studied by Katz and colleagues. Results of the study, published in the scientific journal Disease Management, showed that the program significantly reduced emergency room visits, hospital admissions, length of hospital stays and costs of care over a one-year period. Participants in the current study will receive the program of individualized case management, with or without the addition of the exercise program. A physical activity/cardiac rehabilitation specialist will supervise each participant's exercise program.

"Physical activity has known benefit in heart failure," said Katz, who is director of the Yale-Griffin Prevention Research Center. "We anticipate that this program can help patients stay active and thereby provide significant health benefits. We hope that adults living in the area who have congestive heart failure will talk to their doctors about participating in the study. Subjects will benefit by learning a great deal about how to manage heart failure well, and will help us learn how to further reduce hospitalization and improve health outcomes for those with this common and often serious condition."

Approximately 4.8 million Americans currently have congestive heart failure (CHF), with over 450,000 cases occurring each year. Often the consequence of one or more heart attacks, CHF is the most common cause of hospital admissions among American adults, resulting in more than 900,000 hospitalizations annually. Costs associated with CHF are staggering, exceeding $10 to $15 billion yearly.

In addition to having a diagnosis of CHF, patients in this study will need to meet certain other eligibility criteria. To participate in the study or for further information, contact the Yale-Griffin Prevention Research Center at 732-1265, or

Yale University

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to